Top

Published in:

01-01-2012 | Original paper

Cholecystectomy and risk of pancreatic cancer: a meta-analysis of observational studies

Authors: Genlai Lin, Zhaochong Zeng, Xiaolin Wang, Zheng Wu, Jian Wang, Chenggang Wang, Qiao Sun, Yixing Chen, Hongbo Quan

Published in: Cancer Causes & Control | Issue 1/2012

Abstract

Objective

Data from epidemiological studies related to the association of cholecystectomy and pancreatic cancer (PaC) risk are inconsistent. We conducted a meta-analysis of observational studies to explore this relationship.

Methods

We identified studies by a literature search of Medline (from 1 January 1966) and EMBASE (from 1 January 1974), through 30 June 2011, and by searching the reference lists of pertinent articles. Summary relative risks with their 95% confidence intervals were calculated with a random-effects model. Between-study heterogeneity was assessed using Cochran’s Q statistic and the I ².

Results

A total of 18 studies (10 case–control studies, eight cohort studies) were included in this meta-analysis. Analysis of these 18 studies found that cholecystectomy was associated with a 23% excess risk of PaC (SRR = 1.23, 95% CI = 1.12–1.35), with moderate heterogeneity among these studies (p _{heterogeneity} = 0.006, I ² = 51.0%). Sub-grouped analyses revealed that the increased risk of PaC was independent of geographic location, gender, study design and confounders. There was no publication bias in the current meta-analysis.

Conclusions

The results of this meta-analysis suggest that individuals with a history of cholecystectomy may have an increased risk of pancreatic cancer.

Nathan H, Pawlik TM, Wolfgang CL, Choti MA, Cameron JL, Schulick RD (2007) Trends in survival after surgery for cholangiocarcinoma: a 30-year population-based SEER database analysis. J Gastrointest Surg 11:1488–1496 (discussion 1496–1487)PubMedCrossRef

Turrini O, Cano C, Legoffic A, Delpero JR, Dagorn JC, Iovanna J (2009) Genetic alterations in precancerous pancreatic lesions and their clinical implications. Gastroenterol Clin Biol 33(1028–1035):e1021–e1029

Kuuselo R, Savinainen K, Azorsa DO et al (2007) Intersex-like (IXL) is a cell survival regulator in pancreatic cancer with 19q13 amplification. Cancer Res 67:1943–1949PubMedCrossRef

Bertuccio P, La Vecchia C, Silverman DT et al (2011) Cigar and pipe smoking, smokeless tobacco use and pancreatic cancer: an analysis from the international pancreatic cancer case–control consortium (PanC4). Ann Oncol 22:1420–1426PubMedCrossRef

Tang H, Dong X, Hassan M, Abbruzzese JL, Li D (2011) Body mass index and obesity- and diabetes-associated genotypes and risk for pancreatic cancer. Cancer Epidemiol Biomarkers Prev 20:779–792PubMedCrossRef

Ben Q, Cai Q, Li Z et al (2011) The relationship between new-onset diabetes mellitus and pancreatic cancer risk: a case–control study. Eur J Cancer 47:248–254PubMedCrossRef

Ben Q, Xu M, Ning X et al (2011) Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer 48:1928–1937CrossRef

Shao T, Yang YX (2005) Cholecystectomy and the risk of colorectal cancer. Am J Gastroenterol 100:1813–1820PubMedCrossRef

Ekbom A, Yuen J, Karlsson BM, McLaughlin JK, Adami HO (1996) Risk of pancreatic and periampullar cancer following cholecystectomy: a population-based cohort study. Dig Dis Sci 41:387–391PubMedCrossRef

10.

Chow WH, Johansen C, Gridley G, Mellemkjaer L, Olsen JH, Fraumeni JF Jr (1999) Gallstones, cholecystectomy and risk of cancers of the liver, biliary tract and pancreas. Br J Cancer 79:640–644PubMedCrossRef

11.

Silverman DT, Schiffman M, Everhart J et al (1999) Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer 80:1830–1837PubMedCrossRef

12.

Ko AH, Wang F, Holly EA (2007) Pancreatic cancer and medical history in a population-based case–control study in the San Francisco Bay Area, California. Cancer Causes Control 18:809–819PubMedCrossRef

13.

Arnold LD, Patel AV, Yan Y et al (2009) Are racial disparities in pancreatic cancer explained by smoking and overweight/obesity? Cancer Epidemiol Biomarkers Prev 18:2397–2405PubMedCrossRef

14.

Gullo L, Pezzilli R, Morselli-Labate AM (1996) Risk of pancreatic cancer associated with cholelithiasis, cholecystectomy, or gastrectomy. Dig Dis Sci 41:1065–1068PubMedCrossRef

15.

Lee CT, Chang FY, Lee SD (1996) Risk factors for pancreatic cancer in orientals. J Gastroenterol Hepatol 11:491–495PubMedCrossRef

16.

Ye W, Lagergren J, Nyren O, Ekbom A (2001) Risk of pancreatic cancer after cholecystectomy: a cohort study in Sweden. Gut 49:678–681PubMedCrossRef

17.

Schernhammer ES, Michaud DS, Leitzmann MF, Giovannucci E, Colditz GA, Fuchs CS (2002) Gallstones, cholecystectomy, and the risk for developing pancreatic cancer. Br J Cancer 86:1081–1084PubMedCrossRef

18.

Goldacre MJ, Abisgold JD, Seagroatt V, Yeates D (2005) Cancer after cholecystectomy: record-linkage cohort study. Br J Cancer 92:1307–1309PubMedCrossRef

19.

McDonnell CO, Bailey I, Stumpf T, Walsh TN, Johnson CD (2002) The effect of cholecystectomy on plasma cholecystokinin. Am J Gastroenterol 97:2189–2192PubMedCrossRef

20.

Matters GL, McGovern C, Harms JF et al (2011) Role of endogenous cholecystokinin on growth of human pancreatic cancer. Int J Oncol 38:593–601PubMed

21.

Chu M, Rehfeld JF, Borch K (1997) Chronic endogenous hypercholecystokininemia promotes pancreatic carcinogenesis in the hamster. Carcinogenesis 18:315–320PubMedCrossRef

22.

Narisawa T, Magadia NE, Weisburger JH, Wynder EL (1974) Promoting effect of bile acids on colon carcinogenesis after intrarectal instillation of N-methyl-N′-nitro-N-nitrosoguanidine in rats. J Natl Cancer Inst 53:1093–1097PubMed

23.

Cameron RG, Imaida K, Tsuda H, Ito N (1982) Promotive effects of steroids and bile acids on hepatocarcinogenesis initiated by diethylnitrosamine. Cancer Res 42:2426–2428PubMed

24.

Ura H, Makino T, Ito S et al (1986) Combined effects of cholecystectomy and lithocholic acid on pancreatic carcinogenesis of N-nitrosobis(2-hydroxypropyl)amine in Syrian golden hamsters. Cancer Res 46:4782–4786PubMed

25.

Stroup DF, Berlin JA, Morton SC et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. Jama 283:2008–2012PubMedCrossRef

26.

Bueno de Mesquita HB, Maisonneuve P, Moerman CJ, Walker AM (1992) Aspects of medical history and exocrine carcinoma of the pancreas: a population-based case–control study in the Netherlands. Int J Cancer 52:17–23PubMedCrossRef

27.

Shibata A, Mack TM, Paganini-Hill A, Ross RK, Henderson BE (1994) A prospective study of pancreatic cancer in the elderly. Int J Cancer 58:46–49PubMedCrossRef

28.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188PubMedCrossRef

29.

Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558PubMedCrossRef

30.

Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560PubMedCrossRef

31.

Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101PubMedCrossRef

32.

Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634PubMedCrossRef

33.

Ichimiya H, Kono S, Ikeda M, Tokudome S, Nakayama F, Kuratsune M (1986) Cancer mortality among patients undergoing cholecystectomy for benign biliary diseases. Jpn J Cancer Res 77:579–583PubMed

34.

Wynder EL, Mabuchi K, Maruchi N, Fortner JG (1973) A case control study of cancer of the pancreas. Cancer 31:641–648PubMedCrossRef

35.

Haines AP, Moss AR, Whittemore A, Quivey J (1982) A case–control study of pancreatic carcinoma. J Cancer Res Clin Oncol 103:93–97PubMedCrossRef

36.

Mack TM, Yu MC, Hanisch R, Henderson BE (1986) Pancreas cancer and smoking, beverage consumption, and past medical history. J Natl Cancer Inst 76:49–60PubMed

37.

Cuzick J, Babiker AG (1989) Pancreatic cancer, alcohol, diabetes mellitus and gall-bladder disease. Int J Cancer 43:415–421PubMedCrossRef

38.

Farrow DC, Davis S (1990) Risk of pancreatic cancer in relation to medical history and the use of tobacco, alcohol and coffee. Int J Cancer 45:816–820PubMedCrossRef

39.

Shaffer EA (2005) Epidemiology and risk factors for gallstone disease: has the paradigm changed in the 21st century? Curr Gastroenterol Rep 7:132–140PubMedCrossRef

40.

Borch K, Jonsson KA, Zdolsek JM, Halldestam I, Kullman E (1998) Prevalence of gallstone disease in a Swedish population sample. Relations to occupation, childbirth, health status, life style, medications, and blood lipids. Scand J Gastroenterol 33:1219–1225PubMedCrossRef

41.

Reid FD, Mercer PM, Harrison M, Bates T (1996) Cholecystectomy as a risk factor for colorectal cancer: a meta-analysis. Scand J Gastroenterol 31:160–169PubMedCrossRef

42.

Rosenberg L, Duguid WP, Brown RA (1984) Cholecystectomy stimulates hypertrophy and hyperplasia in the hamster pancreas. J Surg Res 37:108–111PubMedCrossRef

43.

Hyvarinen H, Partanen S (1987) Association of cholecystectomy with abdominal cancers. Hepatogastroenterology 34:280–284PubMed

44.

De Santis A, Attili AF, Corradini SG et al (1997) Gallstones and diabetes: a case–control study in a free-living population sample. Hepatology 25:787–790PubMedCrossRef

45.

Liu B, Balkwill A, Roddam A, Brown A, Beral V (2009) Separate and joint effects of alcohol and smoking on the risks of cirrhosis and gallbladder disease in middle-aged women. Am J Epidemiol 169:153–160PubMedCrossRef

46.

Iodice S, Gandini S, Maisonneuve P, Lowenfels AB (2008) Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg 393:535–545PubMedCrossRef

47.

Jorgensen T (1987) Prevalence of gallstones in a Danish population. Am J Epidemiol 126:912–921PubMed

Title: Cholecystectomy and risk of pancreatic cancer: a meta-analysis of observational studies
Authors: Genlai Lin
Zhaochong Zeng
Xiaolin Wang
Zheng Wu
Jian Wang
Chenggang Wang
Qiao Sun
Yixing Chen
Hongbo Quan
Publication date: 01-01-2012
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 1/2012
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-011-9856-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2012

Sun protective behaviors and vitamin D levels in the US population: NHANES 2003–2006

Factors associated with mortality after breast cancer metastasis

Bodyweight and other correlates of symptom-detected breast cancers in a population offered screening

Improved survival among patients with base of tongue and tonsil cancer in the United States

Why mammography screening has not lived up to expectations from the randomised trials

Occupational risks and lung cancer burden for Chinese men: a population-based case–referent study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer